Repare Therapeutics to Be Acquired by XenoTherapeutics
Repare Therapeutics (RPTX) announces acquisition by XenoTherapeutics for $1.82/share plus contingent value rights, expected to close Q1 2026.
/ 10 items
#BMY↓
Bristol Myers & J&J Halt Key Heart Drug Trial After Weak Results
Bristol Myers Squibb and Johnson & Johnson have stopped a major Phase 3 trial of milvexian for acute coronary syndrome after an interim review showed the drug is unlikely to meet its main goals. Other trials continue with results expected in 2026.
Bristol Myers Squibb Defies Patent Cliff: Blockbuster Sales of Opdivo and Eliquis Drive Raised Forecast
BMS crushed Q3 goals and boosted its yearly forecast. New blockbusters like Opdivo and Eliquis cover losses from older generic drugs.
Pfizer Leads the Way on Drug Pricing and Domestic Investment
Pfizer becomes the first pharmaceutical company to announce a drug-pricing deal with the Trump administration, promising lower prices for up to 100 million patients and committing $70 billion to domestic R&D and manufacturing.